|
Purpose. Observed anti-HER-2 humanized monoclonal antibody trastuzumab monoclonal antibodies (Trastuzumab, trade name: Herceptin Herceptin) for high expression of HER-2 in human ovarian carcinoma cell line SKOV3 xenografts in nude mice inhibited 2. observed song preliminarily explore its mechanism and its first-line ovarian cancer chemotherapy drug cisplatin (diammine dichloro platinum, DDP), docetaxel (Docetaxel, trade name: Taxotere Taxotere) differences on Ovarian Cancer; properly monoclonal antibodies and its combination with cisplatin or (and) differences in the docetaxel and ovarian cancer, first-line chemotherapy (TP program) inhibition of transplanted tumors in nude mice of human ovarian cancer SKOV3. Method for the successful establishment of human ovarian cancer SKOV3 nude mice transplanted tumor model, random bearing nude mice divided into eight groups: ① The Herceptin group, (2) Taxotere group, ③ The DDP group, ④ of Herceptin Taxotere group, ⑤ of Herceptin DDP group, ⑥ Taxotere DDP group, ⑦ of Herceptin Taxotere DDP group, ⑧ control group, n = 4. Herceptin 30mg/kg Taxotere 5mg/kg DDP press 3mg/kg weekly medication via the tail vein, for six weeks, measured weekly once tumors in mice long, short diameter and weight, one week after treatment were sacrificed small mice, inhibitory rate was calculated, HE staining of tumor cell apoptosis, the Tunel detect apoptotic index, immunohistochemical detection of tumor tissue Ki-67 expression. 1. Compared with the control group, the Herceptin monotherapy group can significantly inhibit the growth of human ovarian cancer SKOV3 cells in nude mice transplanted tumor, the difference was statistically significant (P lt; 0.05), but with Taxotere monotherapy group DDP single drug inhibited tumor growth compared, the difference was not statistically significant (P gt; 0.05); compared with the monotherapy group, Herceptin Taxotere joint group, Herceptin DDP duplicate group on tumor growth inhibition. significant, the difference was statistically significant (P lt; 0.05), both compared with Taxotere DDP-linked group, the difference was not statistically significance (P gt; 0.05), and compared between the two, the difference was not statistically significance (P gt; 0.05); compared with the other experimental groups, Herceptin Taxotere DDP triplets of the most significant inhibition of tumor growth, and the difference was statistically significant (P lt; 0.05); 2 by TUNEL detected: Compared with the control group, the apoptosis index of Herceptin monotherapy group was significantly increased, and the difference was statistically significant (P lt; 0.05), but with Taxotere monotherapy group, DDP monotherapy group compared, the difference was not statistically significance (P gt; 0.05); compared with the monotherapy group, Herceptin Taxotere joint group, two joint group of Herceptin DDP apoptotic index increased more significantly, the difference was statistically significant (P lt; 0.05) both compared with Taxotere DDP-linked group, the difference was not statistically significant (P gt; 0.05), and compared between the two, the difference was not statistically significance (P gt; 0.05); Other experimental group phase than triple therapy group apoptotic index of Herceptin Taxotere DDP highest, the difference was statistically significant (P lt; 0.05); Immunohistochemical detection: Compared with the control group, the Herceptin monotherapy group tumor Ki-67 expression rate than the control group significantly decreased, the difference was statistically significant (P lt; 0.05), but with Taxotere monotherapy group, DDP monotherapy group compared, the difference was not statistically significant (P gt; 0.05); compared to the monotherapy group, Herceptin Taxotere joint group, two joint group of Herceptin DDP tumor Ki-67 expression rate decreased more significantly, the difference was statistically significant (P lt; 0.05), but both with Taxotere DDP compared to the associated group, the difference was not statistically significant (P gt; 0.05), and compared between the two, the difference was not statistically significant (P gt; 0.05); compared with the other experimental groups, Herceptin Taxotere DDP triplets tumor Ki-67 expression decreased the most obvious difference was statistically significant (P lt; 0.05). Conclusion 1.Herceptin able to effectively inhibit the high expression of the growth of HER-2 in human ovarian cancer SKOV3 xenografts in nude mice, and can play with ovarian cancer, first-line chemotherapy drug Taxotere, the DDP equivalent tumor inhibition, and its possible mechanism by downregulating Ki -67 such as the expression of inhibition of the proliferation activity of the tumor, and to induce tumor cell apoptosis; 2.Herceptin with Taxotere between, has a synergistic effect between Herceptin and DDP, it can further inhibit the growth of tumors, and Herceptin Taxotere, Herceptin DDP able to play ovarian cancer, first-line chemotherapy TP program equivalent tumor inhibition; 3.Herceptin, Taxotere, DDP, the three drugs in combination to the most significant inhibition of tumor growth, Herceptin can further enhance the the TP programs on tumor growth inhibition.
|